Literature DB >> 21157435

Adeno-associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice.

Hua Li1, Steven Tuyishime, Te-Lang Wu, Wynetta Giles-Davis, Dongming Zhou, Weidong Xiao, Katherine A High, Hildegund C J Ertl.   

Abstract

Using adoptive transfer models we determined that an adeno-associated viral vector of serotype 2 (AAV2) induces in mice proliferation of CD8(+) T cells that recognize an epitope within the viral capsid. Proliferation to an endogenous epitope within viral protein (VP)3 could be observed for at least 3 weeks while a foreign epitope placed at multiple copies within VP2 elicited CD8(+) T cell expansion for at least 10 weeks. These data show that capsid antigens of AAV2 degrade slowly over a period of weeks and during this period provide targets to CD8(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21157435      PMCID: PMC3048183          DOI: 10.1038/mt.2010.267

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  33 in total

1.  Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses.

Authors:  Marcio O Lasaro; Nia Tatsis; Scott E Hensley; J Charles Whitbeck; Shih-Wen Lin; John J Rux; E John Wherry; Gary H Cohen; Roselyn J Eisenberg; Hildegund C Ertl
Journal:  Nat Med       Date:  2008-01-13       Impact factor: 53.440

2.  AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells.

Authors:  Federico Mingozzi; Janneke J Meulenberg; Daniel J Hui; Etiena Basner-Tschakarjan; Nicole C Hasbrouck; Shyrie A Edmonson; Natalie A Hutnick; Michael R Betts; John J Kastelein; Erik S Stroes; Katherine A High
Journal:  Blood       Date:  2009-06-08       Impact factor: 22.113

Review 3.  Self-complementary AAV vectors; advances and applications.

Authors:  Douglas M McCarty
Journal:  Mol Ther       Date:  2008-08-05       Impact factor: 11.454

4.  Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses.

Authors:  Bernd Hauck; Samuel L Murphy; Peter H Smith; Guang Qu; Xingge Liu; Olga Zelenaia; Federico Mingozzi; Jürg M Sommer; Katherine A High; J Fraser Wright
Journal:  Mol Ther       Date:  2008-10-21       Impact factor: 11.454

5.  Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles.

Authors:  Wuping Li; Aravind Asokan; Zhijian Wu; Terry Van Dyke; Nina DiPrimio; Jarrod S Johnson; Lakshmanan Govindaswamy; Mavis Agbandje-McKenna; Stefan Leichtle; D Eugene Redmond; Thomas J McCown; Kimberly B Petermann; Norman E Sharpless; Richard J Samulski
Journal:  Mol Ther       Date:  2008-05-20       Impact factor: 11.454

6.  Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses.

Authors:  Li Zhong; Baozheng Li; Cathryn S Mah; Lakshmanan Govindasamy; Mavis Agbandje-McKenna; Mario Cooper; Roland W Herzog; Irene Zolotukhin; Kenneth H Warrington; Kirsten A Weigel-Van Aken; Jacqueline A Hobbs; Sergei Zolotukhin; Nicholas Muzyczka; Arun Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-29       Impact factor: 11.205

7.  Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo.

Authors:  Chengwen Li; Matt Hirsch; Nina DiPrimio; Aravind Asokan; Kevin Goudy; Roland Tisch; R Jude Samulski
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

8.  A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer.

Authors:  Hua Li; Shih-Wen Lin; Wynetta Giles-Davis; Yan Li; Dongming Zhou; Zhi Quan Xiang; Katherine A High; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2009-04-14       Impact factor: 11.454

9.  Cellular immune response to cryptic epitopes during therapeutic gene transfer.

Authors:  Chengwen Li; Kevin Goudy; Matt Hirsch; Aravind Asokan; Yun Fan; Jeff Alexander; Junjiang Sun; Paul Monahan; David Seiber; John Sidney; Alessandro Sette; Roland Tisch; Jeff Frelinger; R Jude Samulski
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-16       Impact factor: 11.205

10.  A prescription for human immunology.

Authors:  Mark M Davis
Journal:  Immunity       Date:  2008-12-19       Impact factor: 31.745

View more
  22 in total

1.  Regulatory and Exhausted T Cell Responses to AAV Capsid.

Authors:  Gwladys Gernoux; James M Wilson; Christian Mueller
Journal:  Hum Gene Ther       Date:  2017-04       Impact factor: 5.695

2.  Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.

Authors:  Ashley T Martino; Etiena Basner-Tschakarjan; David M Markusic; Jonathan D Finn; Christian Hinderer; Shangzhen Zhou; David A Ostrov; Arun Srivastava; Hildegund C J Ertl; Cox Terhorst; Katherine A High; Federico Mingozzi; Roland W Herzog
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

3.  Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical.

Authors:  Yi He; Marc S Weinberg; Matt Hirsch; Mark C Johnson; Roland Tisch; R Jude Samulski; Chengwen Li
Journal:  Hum Gene Ther       Date:  2013-05-02       Impact factor: 5.695

4.  Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome.

Authors:  TeLang Wu; Katrin Töpfer; Shih-Wen Lin; Hua Li; Ang Bian; Xiang Y Zhou; Katherine A High; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

5.  CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome.

Authors:  Te-Lang Wu; Hua Li; Susan M Faust; Emily Chi; Shangzhen Zhou; Fraser Wright; Katherine A High; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2013-09-30       Impact factor: 11.454

6.  The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing.

Authors:  Christina Raupp; Matthias Naumer; Oliver J Müller; Brittney L Gurda; Mavis Agbandje-McKenna; Jürgen A Kleinschmidt
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

7.  Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates.

Authors:  Hua Li; Marcio O Lasaro; Bei Jia; Shih Wen Lin; Larissa H Haut; Katherine A High; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2011-05-17       Impact factor: 11.454

Review 8.  Immune responses to AAV vectors: overcoming barriers to successful gene therapy.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Blood       Date:  2013-04-17       Impact factor: 22.113

9.  Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia.

Authors:  David M Markusic; Roland W Herzog
Journal:  J Genet Syndr Gene Ther       Date:  2012-01-18

10.  Exposure to wild-type AAV drives distinct capsid immunity profiles in humans.

Authors:  Klaudia Kuranda; Priscilla Jean-Alphonse; Christian Leborgne; Romain Hardet; Fanny Collaud; Solenne Marmier; Helena Costa Verdera; Giuseppe Ronzitti; Philippe Veron; Federico Mingozzi
Journal:  J Clin Invest       Date:  2018-10-22       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.